publication venue for
- Exploring the association between frailty and gynecologic cancer survivorship: a cross-sectional analysis of the Canadian longitudinal study on aging 2023
- Predictors of lifetime cervical cancer screening and association with social determinants of health: cross-sectional evidence from the Canadian longitudinal study on aging 2023
- 34/#806 Patterns of palliative care utilization by women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis 2022
- EP418/#181 Outcomes of positive groin sentinel lymph node biopsies in vulvar squamous cell carcinoma and HPV status: a population based study 2022
- EPV062/#354 Comparison of outcomes between abdominal, minimally invasive and combined vaginal- laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian cervical cancer collaborative) study 2021
- EPV063/#357 The impact of surgical approach in cases with no residual disease on hysterectomy specimen: a 4C (Canadian cervical cancer collaborative) working group study 2021
- EPV254/#148 Septuagenarians and octogenarians undergoing gynecologic oncology laparotomy: is there a role for routine postoperative cardiac biomarker monitoring? 2021
- OP005/#352 Safety of vaginal hysterectomy for cervical cancer: a multicenter cohort study on behalf of the 4C (Canadian cervical cancer collaborative) working group 2021
- 657 Endocrine therapy in advanced endometrioid endometrial cancer: a retrospective analysis of clinicopathologic factors 2021
- EP584 Circulating tumour DNA to monitor tumour activity in endometrial cancer 2019
- EP610 Investigation of patient acceptability of ctDNA in endometrial cancer follow-up 2019
- EP618 The use of preoperative imaging in endometrial cancer: are ontario physicians following GOC guidelines? 2019
- P159 Human uterine cervix-on-a-chip: establishing the first in vitro model to study the development of cervical carcinoma and human papiloma virus mechanism of action 2019
- Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II 2019
- UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR 2015
- DOES GROIN NODE DISSECTION IN VULVAR CANCER DECREASE THE RISK OF GROIN RECURRENCE? 2014
- TIME SERIES ANALYSIS OF GENETICS CONSULTATION FOR PATIENTS WITH SEROUS PELVIC CARCINOMA 2014
- RANDOMISED DOUBLE-BLIND PHASE III TRIAL OF CEDIRANIB (AZD 2171) IN RELAPSED PLATINUM SENSITIVE OVARIAN CANCER: RESULTS OF THE ICON6 TRIAL. 2013
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies 2005
- Validating the diagnostic accuracy of an MRI-based scoring system for differentiating benign uterine leiomyomas from leiomyosarcomas. 34:1027-1033. 2024
- Inguinofemoral sentinel lymph node biopsy by scar injection in vulvar cancer: an assessment of feasibility and long-term outcomes. 32:1512-1518. 2022
- Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. 32:891-898. 2022
- Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic. 32:583-589. 2022
- The role of oophoropexy in patients with gynecological cancer who need radiation therapy. 32:380-388. 2022
- Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. 30:1951-1958. 2020
- Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. 27:437-443. 2017
- Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. 25:1717-1723. 2015
- Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer. 25:809-814. 2015
- An Organizational Guideline for Gynecologic Oncology Services. 25:551-558. 2015
- UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR. 25:69-69. 2015
- Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. 25:125-130. 2015
- Cervical Cancer Incidence in Ontario Women: Differing Sociodemographic Gradients by Morphologic Type (Adenocarcinoma Versus Squamous Cell). 24:1341-1346. 2014
- Performance Status and Symptom Scores of Women With Gynecologic Cancer at the End of Life. 23:971-978. 2013
- Temporal Trends in the Relative Survival Among Women With Cervical Cancer in Canada: A Population-Based Study. 22:1208-1213. 2012
- Characterizing the Learning Curve for Laparoscopic Radical Hysterectomy. 21:930-935. 2011
- Teaching cervical cancer surgery in low- or middle-resource countries.. 20:1604-1608. 2010
- Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only.. 20:1356-1362. 2010
- Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer. 20:979-984. 2010
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium. 20:787-793. 2010
- Malignant Transformation Within Ovarian Dermoid Cysts. 20:75-81. 2010
- cAMP response element–binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. 18:1248-1257. 2008
- Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. 17:1194-1204. 2007
- Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. 16:1536-1544. 2006
- Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. 16:1536-1544. 2006
- First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival. 15:221-221. 2005
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. 15:799-806. 2005
- Steppe by steppe: gynecological oncology on the Mongolian plains. 15:359-360. 2005
- Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy. 13:287-291. 2003
- Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy. 13:287-291. 2003
- Desmoplastic small round cell tumor presenting in the ovaries: Report of a case and review of the literature. 12:760-763. 2002
- A unique BRCA1 mutation identified in Mongolia. 11:241-243. 2001
- Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. 10:463-468. 2000
- Flow cytometric assessment of DNA ploidy is a useful prognostic factor for patients with granulosa cell ovarian tumors. 1:227-232. 1991